330883 RESULTS
COMMENT This paper presents data indicating that palmitoylation of APP in the early secretory pathway regulates its processing by BACE1. The findings are novel and offer a previously unknown aspect of APP biology that could be targeted for therapeutic purposes. T
COMMENT This is a scientifically exciting story that is genetically well controlled, including the conditional knockout of the substrate neuregulin 1. The paper adds muscle spindle formation to the growing list of BACE1 in-vivo functions. Another important aspect
COMMENT Previously, Christian Haass’s group (Willem et al., 2006) and Riqiang Yan’s team (Hu et al., 2006) demonstrated that BACE1 regulates myelination by processing type III NRG1, and that disruption of the BACE1 gene resulted in hypomyelination in the central
COMMENT Like many others, our group was excited about the findings published by Gary Landreth's group (see Cramer et al., 2013) and we repeated the main experiments with short-term dosing of bexarotene in the mutant APPSWE/PS1ΔE9 mouse model. While the ABCA1
COMMUNITY NEWS 2013-07-03 Community News One company cannot own all passive immunotherapies for Alzheimer’s disease, courts in Europe and the UK ruled June 24 and 25, respectively. Specifically, the decisions overturned a 1997 patent, 1,994,937, held by Janssen Alzheimer Immunothe
RESEARCH NEWS 2013-07-03 Research News What determines if APP will be processed to Aβ? Researchers led by Dora Kovacs, Massachusetts General Hospital, Charlestown, present a potential explanation in the July 3 Journal of Neuroscience. They report, for the first time, that APP bin
RESEARCH NEWS 2013-07-03 Research News Release of inflammatory cytokines implicated in Alzheimer’s disease requires signaling through inflammasomes. What regulates these innate immune complexes? A June 30 Nature Immunology paper highlights the essential role of CD36, an Aβ-bindin
RESEARCH NEWS 2013-07-03 Research News Scientists have discovered yet another function for β-secretase (BACE1), the enzyme that kick-starts amyloidogenic processing of the amyloid-β precursor protein. In the June 21 EMBO Journal, researchers led by Carmen Birchmeier, Max Delbrück
Victoria University of WellingtonWellington, New Zealand
RESEARCH MODELS Neuropathology Increased total tau and phosphorylated tau species (Thr181, Ser199, Thr231) in the amygdala and hippocampus starting at three months. Cognition/Behavior Spatial memory deficits starting at five months by the Morris water maze. Olfactory def
RESEARCH MODELS Summary These transgenic mice express mutant human APP with both the Swedish (K670N/M671L) and London (V717I) mutations. They develop age-associated amyloid plaques and cognitive impairment. Neuropathology These mice exhibit age-dependent increases in Aβ4
Colombia
COMMENT I would like to know if there are any facilities currently taking PCA-diagnosed patients for observation and study of this disease. My wife is now 61 and has been diagnosed with PCA. We started seeing symptoms about two years ago but the disease has progr
COMMENT Dr. Hardy's comment that "CNVs may play less of a role in AD than they do in autism or schizophrenia" is based on recently published data from a study, which reported no overrepresentation of specific copy number variations (CNVs) in sporad
COMMENT This is a very interesting finding that directly correlates with our work at Crossbeta. For studying the effect of compounds on the interaction between Aβ oligomers and a receptor present on neurons and inflammatory cells, we have successfully developed a
No filters selected
